3Crawford SY, NaiducciWA, Augustine SC. National survey of quality assurance activities for pharmacy - prepared sterile products in hospitals [J]. Am J Hosp Pharm, 1991, 48( 11 ): 2398 - 413.
4Vogel DP, Eck TA, Witte K. W. Calculation of product waste in Ⅳ Admixture program [J]. AJHP, 1986, 43:952 - 953.
5Paoletti RD, Cerey EW. Reducing costs through centraliazation and standardization of an i. v. admixture program [J]. Am J HealthSyst Pharm, 2000, 57 (12) : 1147 - 1149.
6Hitt CM, Nightingale CH. Cost comparison of single daily i. v. doses of ceftriaxone versus continuous infusion of cefotaxime[J]. Am J Syst Pharm, 1997, 54( 14): 1614- 1618.
7Armour DJ, Caims C J, Costello I, et al. The economics of a pharmacy - based central intravenous additive service for paediatric patients[J]. Pharmacoeconomics, 1996, 10(4): 386- 394.
8Hotchkies L, Grima DT, Hedayati S. The total process cost of parenteral antibiotic therapy: beyond drug acquisition cost [J], Clin Ther, 1996, 18(4): 716 -725.
9Uchida KM, Iteen SA, Wong NT. Identifying costs of intravenous solution wastage [J]. Pharmacoeconomics, 1994, 6(3): 240- 248.
10Milkovich G. Int J Antimicrob Agents [J]. The role of the hospital pharmacist in cost control and antibiotic policy, 2000, 16(3): 291 -294.
